Clinical trials · Dallas–Fort Worth, TX
Muscle Invasive Bladder Urothelial Carcinoma clinical trials in Dallas–Fort Worth
We’re tracking 16 recruiting muscle invasive bladder urothelial carcinoma studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Dallas, TexasAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Dallas, TexasAges 18 years+ - NCT05796375RecruitingPhase 2
Urine testing instead of repeat bladder scope checks
This Phase 2 study tests whether urine tests can help monitor “non-muscle-invasive” bladder cancer without doing as many invasive bladder scopes (cystoscopies). If you qualify, you may be able to replace some scope visits with urine sample testing while still keeping close watch for cancer coming back.
Dallas, TexasAges 18 years+ - NCT05987241RecruitingPhase 2/Phase 3
Using a blood test to guide immunotherapy after bladder/kidney cancer surgery
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
Dallas, TexasAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Dallas, TexasAges 18 years+ - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Dallas, TexasAges 18 years+ - NCT07265947RecruitingPhase 2
Dabogratinib for low grade upper tract urothelial carcinoma
This trial tests a new pill, dabogratinib, for people with low grade cancer in the upper urinary tract (the tubes that carry urine from the kidneys to the bladder). It may help shrink or control the cancer without needing surgery to remove the kidney.
Dallas, TexasAges 18 years+ - NCT07097142RecruitingPhase 3
Shorter radiation for bladder cancer with chemo
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
Dallas, TexasAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Dallas, TexasAges 18 years+ - NCT07673016Recruiting
Collecting urine to test a new bladder cancer detection method
This study collects urine samples to test UroAmp, a new genetic test that may help detect and monitor bladder cancer. It is for people with bladder cancer or blood in urine who want to help improve cancer detection.
Dallas, TexasAges 18 years+ - NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Dallas, TexasAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Dallas, TexasAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Dallas, TexasAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Dallas, TexasAges 18 years+ - NCT07480356RecruitingPhase 3
Testing a new bladder cancer treatment (TARA-002) vs standard chemo
This trial compares a new medicine called TARA-002, given directly into the bladder, to the doctor's choice of standard chemotherapy. It is for people with a high-grade, non-muscle invasive bladder cancer that has not been treated with BCG or has not had BCG recently.
Arlington, TexasAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Arlington, TexasAges 18 years+
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Muscle Invasive Bladder Urothelial Carcinoma trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting muscle invasive bladder urothelial carcinoma studies listed above.
- University of Texas Southwestern Medical Center · 10 studies
- UT Southwestern Medical Center · 4 studies
- Parkland Memorial Hospital · 3 studies
- UT Southwestern Clinical Center at Richardson/Plano · 3 studies
- UT Southwestern/Simmons Cancer Center-Fort Worth · 3 studies
- Urology Clinics of North Texas · 2 studies
- Urology Partners of North Texas · 2 studies
- Cancer Center Outpatient Building
What taking part in a muscle invasive bladder urothelial carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting muscle invasive bladder urothelial carcinoma studies in Texas.
Common questions
- Are there muscle invasive bladder urothelial carcinoma clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 16 recruiting muscle invasive bladder urothelial carcinoma studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a muscle invasive bladder urothelial carcinoma study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a muscle invasive bladder urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New muscle invasive bladder urothelial carcinoma studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.